Abstract:
Site-selective conjugation to biomolecules via thiol-based chemistry is superior to the unselective modification of lysine residues, which produce a mixed product and can potentially interfere with binding affinity of the biomolecule. However, in physiological environments, the maleimide-thiol conjugation product which is the current gold-standard for site-selective thiol-conjugation can be susceptible to hydrolysis or a retro-Michael reaction via exchange with reactive thiols such as those in albumin or glutathione residues yet the degradation is relatively slow. Therefore, for in vivo studies, the maleimide-thiol conjugation proposes instability issues. The compositions and methods disclosed herein provide an alternative thiol-based linkage, one that overcomes the instability issues with conventional reagents and methods. The compositions and methods disclosed herein are useful in various contexts, for example, for 18 F-labeling of peptides/proteins in the preparation of positron emission tomography (PET) probes.
Abstract:
The present invention is directed to cycloalkenyl derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by the GPR120 and / or GPR40 receptors. 5 More particularly, the compounds of the present invention are agonists of GPR120 and / or GPR40, useful in the treatment of, for example, obesity, Type II Diabetes Mellitus, dyslipidemia, etc.
Abstract:
The present disclosure provides various compounds, compositions, and methods of BACE inhibition that interact with both BACE and APP to increase selectivity of the inhibitor. Compounds presented herein exhibit desirably low IC50 values and permeability across the blood-brain barrier.
Abstract:
The present disclosure discloses compounds capable of modulating the activity of α- amino-β-carboxymuconic acid semialdehyde decarboxylase (ACMSD), which are useful for the prevention and/or the treatment of diseases and disorders associated with defects in NAD + biosynthesis, e.g., metabolic disorders, neurodegenerative diseases, chronic inflammatory diseases, kidney diseases, and diseases associated with ageing. The present application also discloses pharmaceutical compositions comprising said compounds and the use of such compounds as a medicament.
Abstract translation:本公开公开了能够调节α-氨基-β-羧基粘康酸半醛脱羧酶(ACMSD)活性的化合物,其可用于预防和/或治疗与以下疾病和病症有关的疾病和病症 NAD +生物合成中的缺陷,例如代谢紊乱,神经退行性疾病,慢性炎症疾病,肾脏疾病和与衰老相关的疾病。 本申请还公开了包含所述化合物的药物组合物以及这些化合物作为药物的用途。 p>
Abstract:
The present invention relates to fluorinated compounds of formula I and methods of synthesizing these compounds. The present invention also relates to pharmaceutical compositions containing the fluorinated compounds of the invention, and methods of treating fibrosis, macular degeneration, diabetic retinopathy (DR), macular edema, diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO), by administering these compounds and pharmaceutical compositions to subjects in need thereof.
Abstract:
The invention provides processes for preparing intermediates useful for preparing compounds of the formula (IV), or a salt thereof, where R 1-3 are as defined in the specification.
Abstract:
Disclosed herein are methods and compounds useful in preparing N-(3,4-dimethyl-5-isoxazolyl)-2-(4-(2-butyl-4-oxo-l,3-diazospiro[4.4]non-l-en-3yl)methyl-2-ethoxymethylphenyl)phenylsulfonamide.
Abstract:
Composés de formule (I); dans laquelle : X représente un groupe hétérocyclique éventuellement substitué; R 1 représente un atome d'hydrogène, un atome d'halogène, un groupe (C 1 -C 6 )alcoxy, un groupe (C 1 - C 6 )alkyle, amino ou NRaRb; R 2 représente un groupe hétérocyclique ou un groupe hétéroaromatique, éventuellement substitués; R 3 représente un atome d'hydrogène, un groupe (C 1 -C 6 )alkyle, un groupe (C 1 -C 6 )alcoxy ou un atome d'halogène; R 4 représente un atome d'hydrogène, un groupe (C 1 -C 4 )alkyle, un groupe (C 1 -C 4 )alcoxy ou un atome de fluor, à l'état de base ou de sel d'addition à un acide. Utilisation en thérapeutique.